Results 201 to 210 of about 36,099,759 (329)

Time, the final frontier

Molecular Oncology, EarlyView.
This article advocates integrating temporal dynamics into cancer research. Rather than relying on static snapshots, researchers should increasingly consider adopting dynamic methods—such as live imaging, temporal omics, and liquid biopsies—to track how tumors evolve over time.
Gautier Follain, Michal Dibus, Omkar Joshi, Guillaume Jacquemet   +3 more
wiley   +1 more source

Complement factor H: a biomarker for progression of cutaneous squamous cell carcinoma.

Journal of Investigative Dermatology, 2014
P. Riihilä, L. Nissinen, R. Ala‐aho, M. Kallajoki, R. Grénman, S. Meri, S. Peltonen, J. Peltonen, V. Kähäri   +8 more
semanticscholar   +1 more source

Mucha H., E. Keller, H. Weber, F. Lingens and W. Trösch, Sirohydrochlorin, a precursor of factor F₄₃₀ biosynthesis in Methanobacterium thermoautotrophicum (1985) FEBS Letters 190, 169‐171 [PDF]

, 1986

openalex   +1 more source

Inhibitor of DNA binding‐1 is a key regulator of cancer cell vasculogenic mimicry

Molecular Oncology, EarlyView.
Elevated expression of transcriptional regulator inhibitor of DNA binding 1 (ID1) promoted cancer cell‐mediated vasculogenic mimicry (VM) through regulation of pro‐angiogenic and pro‐cancerous genes (e.g. VE‐cadherin (CDH5), TIE2, MMP9, DKK1). Higher ID1 expression also increased metastases to the lung and the liver.
Emma J. Thompson, Emma L. Dorward, Kristyn Jurrius, Nathalie Nataren, Markus Tondl, Kay K. Myo Min, Michaelia P. Cockshell, Anahita Fouladzadeh, John Toubia, Mark DeNichilo, Delphine Merino, Claudine S. Bonder   +11 more
wiley   +1 more source

Anti-Factor H Antibody Hemolytic Uremic Syndrome: A Disease in Need of "Make in India" Management. [PDF]

Indian J Nephrol
Lobo V.
europepmc   +1 more source

A New Simple Method of Calculating Thermodynamic Properties of Products of Combustion in Jet Engines and Gas Turbines : 4th Report, The Enthalpy and Entropy of Products of Combustion with Dissociations of CO, H<SUB>2</SUB>, and OH, and Their Dependence on the Excess Air Factor

, 1971
Keikichi TANAKA, Noriyasu ISHIDA, Kiyoshi IDEHARA   +2 more
openalex   +2 more sources

Human complement factor H [PDF]

, 1991
Wilhelm Schwaeble, Helga Schwaiger, Ricardo A. Brooimans, Antonia Barbieri, Johannes Möst, Monica Hirsch‐Kauffmann, Martin Tiefenthaler, David F. Lappin, Mohamed R. Daha, K Whaley, Manfred P. Dierich   +10 more
openalex   +1 more source

MET and NF2 alterations confer primary and early resistance to first‐line alectinib treatment in ALK‐positive non‐small‐cell lung cancer

Molecular Oncology, EarlyView.
Alectinib resistance in ALK+ NSCLC depends on treatment sequence and EML4‐ALK variants. Variant 1 exhibited off‐target resistance after first‐line treatment, while variant 3 and later lines favored on‐target mutations. Early resistance involved off‐target alterations, like MET and NF2, while on‐target mutations emerged with prolonged therapy.
Jie Hu, Ning Ding, Xiaobo Xu, Yedan Chen, Yong Zhang, Jingwen Liu, Jiebai Zhou, Hairong Bao, Donghui Zhang, Yijun Song, Yang Shao, Yuanlin Song   +11 more
wiley   +1 more source

The Role of von Willebrand Factor in the Pathogenesis of C3 Glomerulopathy

Kidney International Reports
Introduction: C3 glomerulopathy (C3G) is caused by dysregulation of complement activation. Our previous study found that patients with C3G showed rare variants in von Willebrand factor (vWF).
Zixin Hua, Yunying Chen, Shasha Han, Xiaojuan Yu, Ying Tan, Feng Yu, Min Chen, Minghui Zhao   +7 more
doaj  

Effective long-term treatment with moss-produced factor H by overcoming the antibody response in a mouse model of C3G. [PDF]

Front Immunol
Tschongov T, Konwar S, Kleindienst J, Dabrowska-Schlepp P, Busch A, Schaaf A, Schell C, Rogg M, Häffner K.   +8 more
europepmc   +1 more source